Abstract

To investigate the effects of cognitive behavioral therapy on the clinical outcomes and self-management behaviors of patients with diabetic peripheral neuropathy treated with prostilbestrol. 204 patients with diabetic peripheral neuropathy treated with prostilbestrol from January 2022 to January 2023 were included in the study and randomly divided into a control group (n=102, receiving usual care) and a cognitive behavioral therapy group (n=102, adding cognitive behavioral therapy to usual care) to compare the intervention effects of the two groups. All summary diabetes self-care activities scores as well as the motor nerve conduction velocity and sensory nerve conduction velocity of the median and common peroneal nerves were higher after the intervention in both groups, with the cognitive behavioral therapy group outperforming the control group (p<0.05). Following the intervention, both groups' ratings on the self-assessment scales for anxiety, sadness, and quality of life in Norfolk diabetic neuropathy dropped, with the cognitive behavioral therapy group scoring lower than the control group (p<0.05). Cognitive behavioral therapy has considerable impacts on diabetic peripheral neuropathy patients who are receiving prostilbestrol treatment, including improvements in their neurophysiological condition, self-management skills, reduction of anxiety and sadness, and quality of life.